A year free of severe sickle cell pain crises: base-edited cells delivered that relief for patients in a trial
Beam Therapeutics reports that its experimental cell therapy, risto-cel, helped patients with sickle cell disease go at least 12 consecutive months without severe pain crises, meeting its Phase 1/2 trial’s primary endpoint. The results were independently adjudicated, but the company has not disclosed the proportion who achieved that outcome or detailed safety data.
Source: biospace.com
Read the original story →